m+Medelevator.RU
← Поиск публикаций
Molecular autism · 2025

Exome sequencing in severe non-syndromic specific learning and language disorders in a French cohort.

СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Viora-Dupont Eléonore, Delanne Julian, Garde Aurore, Nambot Sophie, Colin Estelle, Bournez Marie, Fauconnier-Fatus Clémence, Racine Caroline, Simao De Souza Clément, Bernard Céline, Maurer Agnès, Espitalier Aurélie, Binquet Christine, Bouctot Marion, Humbert Marie-Laure, Briffaut Anne-Sophie, Darmency Véronique, Plumet Patricia, Cotinaud-Ricou Audrey, Relin Noémie, Callier Patrick, Mosca-Boidron Anne-Laure, Marle Nathalie, Tran Mau-Them Frederic, Denommé-Pichon Anne-Sophie, Safraou Hana, Vitobello Antonio, Philippe Christophe, Duffourd Yannis, Bruel Ange-Line, Thauvin-Robinet Christel, Faivre Laurence

Аннотация

BACKGROUND: Specific learning disorders (SLDs) affect approximately 5% of school-age children. In France, genetic investigations of complex non-syndromic SLD cases include chromosomal microarray analysis and fragile X syndrome testing. However, the examples of genes being described in intellectual disability or autism spectrum disorder and also reported in patients with complex and severe SLDs are multiplying. International efforts using exome sequencing have identified monogenic diseases that explain severe SLDs in some instances. The aim of our study was to investigate the value of exome sequencing in children with SLDs without intellectual disability and autism spectrum disorder. METHODS: We initiated a prospective study using exome sequencing in patients with well-documented, severe SLD. RESULTS: Analysis of 82 patients revealed pathogenic/likely pathogenic variants in 11 (13.4%) patients (ADNP, BRAF, CREBBP, KCNN2, KIF1A, RERE, SCN8A, SET, SMARCC2 (x2), TRIO). In addition, 38 variants of uncertain significance in candidate genes for severe neurodevelopmental disorders (NDDs) or in genes of unknown significance that could contribute to the phenotype were identified in 30 patients. LIMITATIONS: The study of 82 patients does not provide sufficient statistical power to conclude that exome testing adds value over chromosomal microarray analysis, or to determine which patient profiles are more likely to benefit from genetic testing. Studies with larger patient numbers are needed to increase statistical power. CONCLUSIONS: This study confirms the involvement of NDD genes in milder phenotypes and suggests the potential of exome sequencing for diagnosing severe SLDs. Further research on larger samples is required to determine which SLDs are most likely to benefit from pangenomic explorations and to clarify the implication of candidate variants.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты